Caffeine's Effect on Regadenoson Administration With Single Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI)

Exclusion Criteria

• •Subject with documented myocardial infarction (MI) ≤ 30 days prior to enrollment
• •Subject with history of percutaneous coronary intervention (PCI) ≤ 4 weeks prior to enrollment
• •Subject with history of coronary artery bypass graft (CABG) ≤ 8 weeks prior to enrollment
• •Subject has prior history of heart transplantation
• •Subject has unstable angina, known severe left main coronary artery stenosis, severe heart failure, uncontrolled arrhythmias, symptomatic hypotension or severe hypertension (systolic blood pressure \< 90 or \> 180 mmHg, respectively), or \> 1st degree atrioventricular block in the absence of a functioning pacemaker
• •Subject requires emergent cardiac medical intervention or catheterization
• •Subject has a history of smoking, regardless of frequency, tobacco type or method of intake, or using any smoking cessation products, including but not limited to the nicotine patch or nicotine gum, within 3 months prior to first dose of regadenoson
• •Subject is currently undergoing treatment with theophylline, or theophylline containing medications within 7 days prior to randomization (Day 3)
• •Subject has a history of known or suspected bronchoconstrictive or bronchospastic lung disease \[e.g., asthma, wheezing, chronic obstructive pulmonary disease (COPD), etc.\]
• •Subject has a history of diabetes associated with gastric disorders and/or emptying
• •Subject has end stage renal disease (ESRD) with a GFR\< 15mL/min or currently undergoing dialysis for ESRD